Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current Concepts and Treatments of Schizophrenia
Piotr Stępnicki, Magda Kondej, Agnieszka A. Kaczor
Molecules (2018) Vol. 23, Iss. 8, pp. 2087-2087
Open Access | Times Cited: 467

Showing 1-25 of 467 citing articles:

Mapping neurotransmitter systems to the structural and functional organization of the human neocortex
Justine Y. Hansen, Golia Shafiei, Ross D. Markello, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 11, pp. 1569-1581
Open Access | Times Cited: 412
The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research
Steven G. Potkin, John M. Kane, Christoph U. Correll, et al.
Schizophrenia (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 283
The Roles of Serotonin in Neuropsychiatric Disorders
Mahsa Pourhamzeh, Fahimeh Ghasemi Moravej, Mehrnoosh Arabi, et al.
Cellular and Molecular Neurobiology (2021) Vol. 42, Iss. 6, pp. 1671-1692
Closed Access | Times Cited: 216
Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials
Meenakshi Dauwan, Marieke J.H. Begemann, Margot I. E. Slot, et al.
Journal of Neurology (2019) Vol. 268, Iss. 4, pp. 1222-1246
Open Access | Times Cited: 184
Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees
Iris M. Otani, Heather K. Lehman, Artemio M. Jongco, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 5, pp. 1525-1560
Open Access | Times Cited: 111
Male sex bias in early and late onset neurodevelopmental disorders: Shared aspects and differences in Autism Spectrum Disorder, Attention Deficit/hyperactivity Disorder, and Schizophrenia
Sofia Santos, Helena Ferreira, João Martins, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 135, pp. 104577-104577
Open Access | Times Cited: 97
The Role of Diet as a Modulator of the Inflammatory Process in the Neurological Diseases
Antonina Kurowska, Wojciech Ziemichód, Mariola Herbet, et al.
Nutrients (2023) Vol. 15, Iss. 6, pp. 1436-1436
Open Access | Times Cited: 68
5-HT3Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface
Gohar Fakhfouri, Reza Rahimian, Jonas Dyhrfjeld‐Johnsen, et al.
Pharmacological Reviews (2019) Vol. 71, Iss. 3, pp. 383-412
Open Access | Times Cited: 88
Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment
Anna Stasiłowicz-Krzemień, Anna Tomala, Irma Podolak, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 778-778
Open Access | Times Cited: 76
Intranasal delivery of Clozapine using nanoemulsion-based in-situ gels: An approach for bioavailability enhancement
Nourhan A. Abdulla, Gehan F. Balata, Hanaa A. Elghamry, et al.
Saudi Pharmaceutical Journal (2021) Vol. 29, Iss. 12, pp. 1466-1485
Open Access | Times Cited: 67
Glutamatergic dysfunction in Schizophrenia
Andreas O. Kruse, Juan Bustillo
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 66
New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
Jolanta Orzelska‐Górka, Joanna Mikulska, Anna Wiszniewska, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10624-10624
Open Access | Times Cited: 63
The dual hit hypothesis of schizophrenia: Evidence from animal models
Cyprien G.J. Guerrin, Janine Doorduin, Iris E. Sommer, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 131, pp. 1150-1168
Open Access | Times Cited: 56
Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia
Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, et al.
Pharmacology & Therapeutics (2022) Vol. 236, pp. 108236-108236
Open Access | Times Cited: 52
Schizophrenia: The new etiological synthesis
Markus J. Rantala, Severi Luoto, Javier I. Borráz-León, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 142, pp. 104894-104894
Open Access | Times Cited: 47
Schizophrenia, Bipolar and Major Depressive Disorders: Overview of Clinical Features, Neurotransmitter Alterations, Pharmacological Interventions, and Impact of Oxidative Stress in the Disease Process
Pravat K. Mandal, Shradha Gaur, Rimil Guha Roy, et al.
ACS Chemical Neuroscience (2022) Vol. 13, Iss. 19, pp. 2784-2802
Closed Access | Times Cited: 45
Exosomes in brain diseases: Pathogenesis and therapeutic targets
Qingying Si, Linlin Wu, Deshui Pang, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 32
Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
Eric D. Achtyes, Seth C. Hopkins, Nina Dedic, et al.
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1543-1556
Open Access | Times Cited: 31
Neuromodulatory control of complex adaptive dynamics in the brain
James M. Shine
Interface Focus (2023) Vol. 13, Iss. 3
Open Access | Times Cited: 25
Neuroinflammation and Schizophrenia: New Therapeutic Strategies through Psychobiotics, Nanotechnology, and Artificial Intelligence (AI)
Freiser Eceomo Cruz Mosquera, Maria Camila Guevara-Montoya, Valentina Serna-Ramirez, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 4, pp. 391-391
Open Access | Times Cited: 16
Beyond dopamine: Novel strategies for schizophrenia treatment
Paulina Dudzik, Klaudia Lustyk, Karolina Pytka
Medicinal Research Reviews (2024) Vol. 44, Iss. 5, pp. 2307-2330
Closed Access | Times Cited: 13
New clues for the role of cerebellum in schizophrenia and the associated cognitive impairment
Pawan Faris, Doris Pischedda, Fulvia Palesi, et al.
Frontiers in Cellular Neuroscience (2024) Vol. 18
Open Access | Times Cited: 11
Multi-Target Approach for Drug Discovery against Schizophrenia
Magda Kondej, Piotr Stępnicki, Agnieszka A. Kaczor
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 3105-3105
Open Access | Times Cited: 80
Clozapine: Why Is It So Uniquely Effective in the Treatment of a Range of Neuropsychiatric Disorders?
Dara Gammon, Catherine Cheng, Anna Volkovinskaia, et al.
Biomolecules (2021) Vol. 11, Iss. 7, pp. 1030-1030
Open Access | Times Cited: 52
Exploring the Relationship Between Schizophrenia and Cardiovascular Disease: A Genetic Correlation and Multivariable Mendelian Randomization Study
Rada R Veeneman, Jentien M. Vermeulen, Abdel Abdellaoui, et al.
Schizophrenia Bulletin (2021) Vol. 48, Iss. 2, pp. 463-473
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top